Predictors of Neurohormonal and Hemodynamic Effects of Candesartan in Hf Patients Treated With an Ace Inhibitor
Simon de Denus(Montreal Heart Institute), M. White, Anique Ducharme(Montreal Heart Institute), Marie‐Pierre Dubé(Montreal Heart Institute), Eileen O’Meara(Montreal Heart Institute), Normand Racine(Montreal Heart Institute), Simon Kouz, Jean‐Claude Lavoie(Centre Hospitalier Universitaire Sainte-Justine), Jean‐Claude Tardif(Montreal Heart Institute), A. Mansour(Montreal Heart Institute), Jacques Turgeon(Unknown), Thao Huynh(AstraZeneca (United Kingdom)), M. Phillips, Jean L. Rouleau(Montreal Heart Institute), M Leblanc, Serge Lepage, Dominique Dion, Marie‐Claude Guertin
Cited by 0
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
|New England Journal of Medicine|2018|3.2k
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
|New England Journal of Medicine|2015|2.3k
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
|New England Journal of Medicine|2012|2k